PRPF3 and systemic mastocytosis: Wecompared the two subgroups of SM patients with and without cutaneoussymptoms, called SM+C and SM-C, and identified some significant differences.PRP-3, PRP-3 desR106, P-C peptide, statherin desF43, and P-B des1-5 were more abundant in SM-C than in the SM+C subgroup(Figure 2A–E).